Canadian class-action settlement offers $8M for healthcare trust investors
Eligible investors who bought DRI Healthcare Trust securities between Feb. 2021 and Aug. 2024 can claim compensation; settlement hearing scheduled for Sept. 22, 2026.
The day's top stories, food & events — every morning at 7. Unsubscribe anytime.
Canadians who invested in DRI Healthcare Trust securities could soon cash in on an $8-million class-action settlement announced Friday.
Kalloghlian Myers LLP reached the settlement against DRI Healthcare Trust, which describes itself as a "pioneer in global pharmaceutical royalty monetization." The trust holds a portfolio of 18 pharmaceutical royalties from 14 different pharmaceutical products across eight therapeutic areas.
The class action alleges that DRI made misrepresentations in its public disclosure. The settlement is a compromise of disputed claims and is not an admission of liability or wrongdoing by DRI Healthcare Trust or any other defendant.
Who's eligible: anyone who acquired DRI securities between February 11, 2021, at 9:30 a.m. ET and August 6, 2024, at 5:38 p.m. ET, and held those securities through the open of trading on July 8, 2024, or until the end of the class period.
The settlement approval hearing, previously scheduled for May 22, 2026, has been rescheduled to September 22, 2026. Class counsel's fees will not exceed 33.3 per cent of the settlement amount, plus reimbursement for expenses and a 10 per cent levy to the class proceedings fund.
Those who want to object have until September 1, 2026. To opt out entirely, submit a form by August 18, 2026. For more information, contact dri@kalloghlianmyers.com or visit the law firm's class action site.